DEADLINE ALERT For LNTH And CYTK: The Law Offices Of Frank R. Cruz Reminds Investors Of Class Actions On Behalf Of Shareholders

(MENAFN- GlobeNewsWire - Nasdaq) LOS ANGELES, Sept. 19, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to ... .

Lantheus Holdings, Inc. (NASDAQ: LNTH )
Class Period: February 26, 2025 – August 5, 2025
Lead Plaintiff Deadline: November 10, 2025

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Lantheus did not have an accurate understanding of the pricing and competitive dynamics of Pylarify's market; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you are a Lantheus shareholder who suffered a loss, click here to participate.

Cytokinetics, Incorporated (NASDAQ: CYTK )
Class Period: December 27, 2023 – May 6, 2025
Lead Plaintiff Deadline: November 17, 2025

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Defendants had knowingly or recklessly omitted a REMS from the initial NDA submission, despite prior FDA discussions about safety and risk mitigation; (2) the subsequent REMS submission necessitated a three-month delay in the FDA's process for potential approval; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you are a Cytokinetics shareholder who suffered a loss, click here to participate.

Follow us for updates on Twitter: twitter/FRC_LAW .

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to ... , or visit our website at . If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
...

MENAFN19092025004107003653ID1110085380